The Predictive Value of MLR for Radiation Pneumonia During Radiotherapy of Thoracic Tumor Patients

Ya Gao, Xinyi Wu, Yunhao Li, Yifei Li, Qingyu Zhou, Qiongqiong Wang, Chaoyi Wei, Deli Shi, Congying Xie, Huanle Pan

Department of Radiotherapy and Chemotherapy, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, People’s Republic of China

Purpose: To evaluate the predictive value of blood lymphocyte, monocyte to lymphocyte ratio (MLR), and neutrophil to lymphocyte ratio (NLR) for radiation pneumonia (RP) in patients with thoracic tumors receiving radiotherapy.

Patients and Methods: The clinical data of 65 patients with thoracic tumor (esophageal cancer, lung cancer) treated by radiotherapy in our hospital were retrospectively analyzed. Patients were divided into the RP group and the non-RP group according to the Common Terminology Criteria for Adverse Events (CTCAE 5.0). Data on blood cell counts, including lymphocytes, monocytes, and neutrophils, were collected before (0 weeks) and after 1, 2, and 4 weeks of radiotherapy.

Results: Of the 65 patients enrolled, 27 developed radiation pneumonia and 38 did not. Patients’ clinical factors, including age, TNM stage, tumor type, underlying lung disease, and history of smoking, had no correlation with RP. ANOVA of repeated measurement data showed that the changes of MLR in the group with RP during radiotherapy were significantly different from those in the non-RP group (P<0.05). The RP prediction model based on the identified risk factors was established using receiver operator characteristic curves. The results showed that the area under the curve for the monocyte to lymphocyte ratio was 0.755 (95% CI, 0.63–0.87, P=0.000), and the best cutoff point for MLR was 0.426.


Keywords: cancer, radiotherapy, radiation pneumonitis, monocyte to lymphocyte ratio

Introduction

Radiotherapy (RT) is a major therapeutic strategy for patients with lung cancer. Radiation-induced lung injury (RILI) is a common dose-limiting complication of thoracic radiotherapy that usually consists of radiation pneumonitis (RP) and radiation fibrosis (RF).1–4 The symptoms of RP are cough, asthma, and even respiratory failure. It affects quality of life greatly, and may even lead to death.5

Recent clinical data have demonstrated that the incidence of irradiation-related pulmonary injury among patients with cancer who received radiotherapy ranged from 20.3% to 36.9%.6–8

More and more studies suggest that the inflammation background of the host had an influence on the incidence of RILI.9,10 Some evidence from preclinical and clinical investigations supports that recruitment or local infiltration of T lymphocytes had a causal connection with the complex inflammation course of...
RP and became a common characteristic of RP. More importantly, detection of T lymphocyte subsets undertaken by flow cytometric analysis found that CD4\(^+\) T lymphocytes remarkably accumulated during the radioactive pneumonia period in patients with lung cancer. Zhou et al’s research found that lower peripheral blood levels of lymphocytes and CD4\(^+\) T lymphocytes were associated with an increased risk of RP, which was associated with differences in radiation-induced lung toxicity among individuals and helped identify those who were susceptible to developing RP after RT. In addition, CBC-derived inflammatory biomarkers such as the systemic immune inflammation index (SII), neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR), and monocyte to lymphocyte ratio (MLR) were also used as prognostic factors in various malignancies. These biomarkers are based on two or three parameters related to neutrophils, lymphocytes, platelets, and monocytes. NLR, PLR, and MLR have been used as markers in systemic inflammation and are associated with poor outcomes in solid malignancies. The neutrophil to lymphocyte ratio (NLR), which involves measurement of a subgroup of white blood cells, has been identified as a marker of systemic inflammation. Lee et al conducted a retrospective analysis of patients with stage III non-small cell lung cancer receiving concurrent chemoradiation and found that patients with symptomatic radiation pneumonitis had higher NLR and C-reactive protein levels (P=0.067 and P=0.012, respectively). The NLR was statistically significant for progression of radiation pneumonia to symptomatic pneumonia. Pan et al found that combining NLR, V20, and mean lung dose could predict radiation-induced lung injury in lung cancer patients receiving concurrent IMRT and chemotherapy. It was also found that the pre-treatment NLR level was a representative indicator of systemic inflammation and was associated with RILI grade 3 or higher. However, the relationship between MLR and RILI has not been well discussed before.

We retrospectively analyzed changes of serum levels of lymphocyte, NLR, and MLR during the radiotherapy treatment period in 65 patients enrolled in the present study. Meanwhile, the prediction model based on the identified risk factors was established using receiver operator characteristic curves. We intended to explore an economic and convenient prediction model of radiation pneumonitis during radiotherapy (RT) in thoracic malignant tumor patients.

Patients and Methods
Patient Population
Sixty-five pathologically confirmed patients with esophageal and lung cancer treated in the First Affiliated Hospital of Wenzhou Medical University from 2014 to 2019 were retrospectively collected. The inclusion conditions were as follows: patients with thoracic malignancies receiving radiation therapy who had an expected survival of more than 6 months and an ECOG score of ≤4. We excluded those who had incomplete RT, inflammation, or who had hematological diseases. All patients signed informed consent. The study was approved by the Ethics Committee of the First Affiliated Hospital of Wenzhou Medical University.

Treatment Regimen
All patients received Intensity Modulated Radiation Therapy (IMRT) and 3-dimensional conformal radiation therapy (3D-CRT). The total tumor volume (GTV), clinical volume (CTV), and planned target volume (PTV) were determined according to the definitions reported in ICRU 50 and 62. The median dose of radiotherapy was 56 Gy. The criteria for receiving a treatment plan are: at least 99% of the planned target volume (PTV) is covered by 95% of the prescribed dose, and the maximum dose is less than or equal to 105%. We apply normal tissue dose–volume restrictions. The limited volume of the spinal cord was not allowed to be more than 45 Gy. The average dose to the heart receiving more than 35 Gy was limited. The average esophagus dose should not exceed 34 Gy. Normal lung total volume was defined as the volume of both lungs minus the total target volume (GTV). V20 was no more than 30% in both lungs, V5 ≤50%, and the average dose was no more than 17 Gy. The dosage of RT was delivered with 6 MV X-ray by linear accelerator.

Detection of Peripheral Blood
Data on blood cell counts of all patients were performed in peripheral blood samples using standard phlebotomy techniques at four time points: at baseline (within 1 week prior to irradiation), and at an interval of 1, 2, and 4 weeks during RT. The blood lymphocyte, mononuclear cell, and neutrophil subsets of 65 patients were detected at the same time points.

Diagnosis of Radiation-Induced Lung Injury
History, physical examination, and chest CT scan were checked at each follow-up. Generally, chest CT scans
were performed 1, 3, and 6 months after radiotherapy. In acute pneumonia, chest CT showed hyperemia and exudation of the lung, increased texture and small pieces of shadow, and the edge was fuzzy. If the treatment continued without remission, chronic pulmonary fibrosis would appear, which was characterized by a strip shadow in the radiation area, fiber contraction, mediastinal or tracheal displacement, and grid or honeycomb changes in severe cases. Generally, 1–2 grade radiation lung injury had no clinical symptoms and did not require routine clinical treatment. However, patients with grade 3 and above had obvious dry cough, shortness of breath, and symptoms of hypoxia, requiring clinical treatment. If the patient developed fever, dry cough, and other suspected symptoms during radiotherapy, chest CT should be used to observe lung images, and blood routine was also performed. If CRP and PCT were increased, it often indicated bacterial infection, and further identification of sputum culture. RP was diagnosed by CTCAE 5.0 evaluation criteria as follows: continuous cough and/or dyspnea occur in patients with radiation pneumonia of grade (≥2) and need to be treated clinically. The chest CT scan showed a patchy or strip shadow in the radiation area, and honeycomb-like changes in severe cases.

Statistical Analysis
SPSS 25.0 and GraphPad Prism 8.0.2 were adopted to analyze the data. The chi-square test was performed to test the categorical variables. Repeated measures of analysis of variance (ANOVA) was performed to detect whether serum indicators had statistical significance between the two groups. The ROC curve prediction model was established, and the predictive value of serum inflammatory marker on radiation pneumonitis was evaluated by analyzing the area under the curve. All P values less than 0.05 were considered statistically significant.

Results
A total of 65 patients with lung cancer and esophageal cancer were enrolled, of which 39 were lung cancer and 26 were esophageal cancer. The characteristics of the patients are shown in Table 1. There were 59 male patients and 6 female patients, with a median age of 65 years (ranging from 43 to 86 years). Of these 65 patients, 55 received concurrent chemoradiotherapy and 10 received radiotherapy alone. A total 41.5% of these patients received 50 to 60 Gy of radiation, and 35.3% received no less than 60 Gy. The median radiotherapy dose was 56 Gy. According to the general term standard for adverse events (CTCAE, version 5.0), patients with radiation pneumonia were evaluated. In total, 27 patients (41.5%) developed grade 2 or higher RP, including 17 cases of grade 2, 5 cases of grade 3, 3 cases of grade 4, and 2 cases of grade 5. These events were frequently observed within 1 to 3 months after radiotherapy. There was no significant difference in gender, age, tumor type, TNM stage, and treatment mode between the two groups, while the ECOG score was significantly different between the two groups (P<0.05).

Changes in Lymphocyte Levels During Radiotherapy
Figure 1 presents the level of lymphocyte in patients during radiotherapy between the two groups. Our study illustrated that there was no significant difference in lymphocytes between the RP and non-RP groups. Serum lymphocyte concentrations in both groups were lower than 2.0×10^9/L.

Changes in NLR Levels During Radiotherapy
The NLR value of the RP group decreased to a low value within the first week of radiotherapy, with an inflection point, and then showed a continuous trend of increasing (Figure 2). While in patients with non-RP, the NLR value showed a continuous and slowly increasing trend, and no obvious inflection point appeared. The NLR final value of patients with RP after 4 weeks of radiotherapy was higher than that of the non-RP group. However, the difference of NLR between the two groups was not significant (P>0.05).

Changes in MLR Levels During Radiotherapy
Different from the level of lymphocyte and NLR, there was a statistically significant difference in the level of MLR between the RP group and the non-RP group after 2 weeks of radiotherapy (P<0.05). Results demonstrated that the final MLR value of patients with RP was higher, and the difference was statistically significant (P<0.05), which is shown in Figure 3.

Predictive Risk Assessment Model of RP
In order to establish a better prediction model, we established a ROC curve for MLR. The results showed that the area under the curve for the monocyteto lymphocyte ratio was 0.755 (95% CI, 0.63–0.87, P<0.000), and the best
Table 1 Patients Characteristics (n=65)

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>RP (N=27)</th>
<th>Non-RP (N=38)</th>
<th>Total (N=65)</th>
<th>( \chi^2 )</th>
<th>P values</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>26</td>
<td>33</td>
<td>59</td>
<td>0.745</td>
<td>0.388</td>
</tr>
<tr>
<td>Female</td>
<td>1</td>
<td>5</td>
<td>6</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age, years</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;65</td>
<td>13</td>
<td>17</td>
<td>30</td>
<td>0.074</td>
<td>0.786</td>
</tr>
<tr>
<td>≥65</td>
<td>14</td>
<td>21</td>
<td>35</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ECOG</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0–2</td>
<td>17</td>
<td>34</td>
<td>51</td>
<td>6.565</td>
<td>0.01*</td>
</tr>
<tr>
<td>3–4</td>
<td>10</td>
<td>4</td>
<td>14</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Smoke</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>14</td>
<td>24</td>
<td>38</td>
<td>0.831</td>
<td>0.362</td>
</tr>
<tr>
<td>No</td>
<td>13</td>
<td>14</td>
<td>27</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chemotherapy</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>22</td>
<td>33</td>
<td>55</td>
<td>0.058</td>
<td>0.809</td>
</tr>
<tr>
<td>No</td>
<td>5</td>
<td>5</td>
<td>10</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Basic lung disease</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>2</td>
<td>2</td>
<td>4</td>
<td>0.000</td>
<td>1.000</td>
</tr>
<tr>
<td>No</td>
<td>25</td>
<td>36</td>
<td>61</td>
<td></td>
<td></td>
</tr>
<tr>
<td>TNM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I–II</td>
<td>8</td>
<td>7</td>
<td>15</td>
<td>1.117</td>
<td>0.291</td>
</tr>
<tr>
<td>III–IV</td>
<td>19</td>
<td>31</td>
<td>50</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GTV dose (Gy)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;56</td>
<td>14</td>
<td>16</td>
<td>30</td>
<td>0.698</td>
<td>0.403</td>
</tr>
<tr>
<td>≥56</td>
<td>13</td>
<td>22</td>
<td>35</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tumor type</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Esophageal</td>
<td>12</td>
<td>14</td>
<td>26</td>
<td>0.380</td>
<td>0.538</td>
</tr>
<tr>
<td>Lung cancer</td>
<td>15</td>
<td>24</td>
<td>39</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Note: *P<0.05.
Abbreviations: RP, radiation pneumonia; GTV, gross tumor volume.

cutoff point for MLR was 0.426. The ROC curve is shown in Figure 4.

Discussion

The mechanism of radiation-induced lung injury is still unclear, but it is currently recognized that its occurrence was a complex process involving a variety of cytokines and immune and inflammatory factors, especially inflammatory cytokines and lymphocytes, which caused damage to endothelial cells, parenchymal cells, vasculature, stroma, and the tissue microenvironment.19 In view of the pathological development of the disease, patients with advanced pulmonary fibrosis have a poor quality of life and a high mortality rate. In view of the above facts, there is an urgent need to explore prognostic biomarkers that are easily evaluated for patients with radiotherapy.

In this study, changes in MLR during radiotherapy were statistically different in the group with and without RP. Especially 2 weeks after radiotherapy, the difference between the two groups was obvious. MLR values started to increase in both groups after radiotherapy, but the patients in the RP group had a relatively slow upward trend at 1 week after radiotherapy, and then increased rapidly, and the final value was higher than that in the non-RP group. However, the difference was not statistically significant in lymphocytes. We found that after the start of radiotherapy, lymphocytes in both groups showed a decreasing trend. The decline in the RP group was relatively gentle and the final value was lower at 4 weeks. Zhou et al’s clinical retrospective study found
that lymphocyte levels decreased markedly in patients who developed grade 2 or 3 RP compared with patients with grade 0 or 1 RP from the second to the sixth week of the RT start. Furthermore, they found a sharp increase in WBCs and neutrophils at week 12 post irradiation in patients who experienced grade 3 RP. Maybe it was due to the lack of time nodes in our study, which was inconsistent with previous research. Numerous research studies showed that a decrease in circulating lymphocytes could be due to lymphocytes infiltrating into the pulmonary interstitium, and it may reasonably explain the decrease in circulating lymphocytes during pre-RP and RP. Radiation activates the inflammatory cascade, neutrophils can secrete cytokines, and chemokines mediate the recruitment of inflammatory cells and angiogenesis. In addition, elevated neutrophils can suppress the cytolytic activity of lymphocytes, natural killer cells, activated T cells, and suppression of adaptive immune responses. Current studies have shown that NLR can predict the occurrence of radiation pneumonia in patients with NSCLC who received concurrent radiotherapy and chemotherapy. Pan et al found that combining NLR,
V20, and mean lung dose could predict radiation-induced lung injury in lung cancer patients receiving concurrent IMRT and chemotherapy. Multivariate analysis showed that total dose ≥60 Gy, V20 ≥20%, mean lung dose ≥12 Gy, and NLR ≥2.2 were still independent predictors of RP (P=0.010, 0.043, 0.028, and 0.015, respectively). It was also found that the pre-treatment NLR level was a representative indicator of systemic inflammation and was associated with RILI grade 3 or higher. However, the exact mechanism of this effect remains unclear. The most likely reason is that the host’s inflammatory response is involved in the occurrence and development of RP.

In our study, it was also found that the baseline NLR and MLR levels of patients with RP before radiotherapy (week 0) were higher than those without RP, and the baseline NLR level was greater than 2.2; however, further research was still needed to confirm. In order to improve the predictive power of RP, analysis of MLR was carried out by ROC model. The area under the combined curve of MLR was 0.755 (95% CI, 0.63–0.87, P=0.000). The results show that MLR could further improve the prediction ability. In addition, we have found the ECOG in the clinical data was significantly different between the two groups (P=0.05). Deng et al found that only COPD had a significant difference between the two groups with and without radiation pneumonia, and no significant abnormalities were found in smoking and chemotherapy. Otherwise, few studies currently suggest that certain chemotherapy and concurrent chemotherapy may increase the risk of RP. Some limitations existed in the present study. First, the number of patients was small. Second, this study was limited by selection biases due to its single-center and retrospective nature. Thus, prospective studies to verify the impact of MLR level in thoracic tumor patients treated by radiotherapy are needed to confirm these preliminary results.

**Conclusion**

In conclusion, this study indicates that MLR may be an available serum biomarker in the early stage of RT, which may provide a convenient and non-invasive method for early detection, early intervention, and treatment in patients who undergo thoracic radiotherapy.

**Funding**

The study is partially supported by funding from Wenzhou Municipal Science and Technology Bureau (H20180003).

**Disclosure**

The authors report no conflicts of interest in this work.

**References**


